RecruitingNCT06105710

Mechanistic Insights From Bronchoscopy Airway Samples

Sponsor

University of California, San Francisco

Enrollment

24 participants

Start Date

Jul 1, 2024

Study Type

OBSERVATIONAL

Conditions

Asthma

Summary

The purpose of this study is to examine the mechanisms of asthma. The investigators are comparing the cells of individuals with and without asthma and looking at the roles various parts of the cell play in the production and secretion of mucus.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria11

Healthy Controls
Male and female subjects between the ages of 18 and 70 years
Ability to provide written informed consent and ability to comply with the requirements of the study
No hyperreactivity to methacholine (PC20 FEV1 Methacholine \>16 mg/mL)
No history of allergic rhinitis/seasonal allergies
Asthmatics
Male and female subjects between the ages of 18 and 70 years
Ability to provide written informed consent and ability to comply with the requirements of the study
History of asthma
No use of oral or inhaled corticosteroids for the treatment of asthma during the past 6 weeks
Hyperreactivity to methacholine (PC20 FEV1 Methacholine \< 8 mg/ml)

Exclusion Criteria18

Current smokers, defined by (a) \>5 cigarettes smoked in past 12 months, and (b) ≤ 8 weeks since last time smoking; or former smokers who have a total smoking history
pack-years
Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
Subjects with a history of lung disease other than asthma
Subjects with a history of prior esophageal hernia surgery
Subjects with a history of a medical disease, which in the opinion of the Investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study
Current participation in an investigational drug trial
Prohibited Medications and Treatments The following medications are prohibited during the study and must be discontinued prior to enrollment for the amount of time specified below.
Astemizole: 12 weeks
Steroids (oral, inhaled or nasal): 6 weeks
Nedocromil sodium, sodium cromoglycate: 4 weeks
Long-acting methylxantines: 2 days
Short-acting methylxantines: 12 hours
Montelukast: 7 days
Zafirlukast: 7 days
Salmeterol: 2 days
Omalizumab: 6 months
Medications to be withheld prior to bronchoscopy: Aspirin or Non- steroidal anti-inflammatory agents (NSAIDs) for 2 days Medications to be withheld before each clinic visit: Short-acting bronchodilators (e.g. Albuterol) for 6 hours; Short-acting anti- cholinergics (e.g. Atrovent, Combivent) for 8 hours; and antihistamines (e.g. Benadryl, Claritin) for 3 days.